GHANA MAKES HISTORY AS FIRST TO APPROVE NEW MALARIA VACCINE FROM OXFORD. (PHOTO).

Ghana Makes History As First To Approve New Malaria Vaccine From Oxford

Ghana has become the first country in the world to approve a new malaria vaccine from Oxford University.

The vaccine called R21 appears to be hugely effective in stark contrast to previous ventures in the same field.

Trial data from preliminary studies in Burkina Faso showed the R21 vaccine was up to 80 per cent effective when given as three initial doses, and a booster a year later, BBC reports.

Children under the age of three years old are in line to benefit from the vaccine.

Ghana’s drug regulators have assessed the final trial data on the vaccine’s safety and effectiveness, which is not yet public, and have decided to use it.

The World Health Organisation is also considering approving the vaccine. Malaria kills about 620,000 people each year, most of them young children.

It has been a massive, century-long, scientific undertaking to develop a vaccine that protects the body from the malaria parasite, BBC said.

It noted, however, that the widespread use of the vaccine hinges on the results of a larger trial involving nearly 5,000 children. These had been expected to take place at the end of last year, but have still not been formally published. However, they have been shared with some government bodies in Africa and scientists.

Other African countries are also studying the data, as is the WHO

Director of the Jenner Institute at the University of Oxford, Prof Adrian Hill, where the vaccine was invented, says African countries are declaring “we’ll decide”, after being left behind in the rollout of Covid-19 vaccines during the pandemic.

He told me: “We expect R21 to make a major impact on malaria mortality in children in the coming years, and in the longer term [it] will contribute to the overall final goal of malaria eradication and elimination.”

The Serum Institute of India is preparing to produce between 100-200 million doses per year, with a vaccine factory being constructed in Accra, Ghana.

Each dose of R21 is expected to cost a couple of dollars.

The CEO of the Serum Institute, Adar Poonawalla, told BBC that “Developing a vaccine to greatly impact this huge disease burden has been extraordinarily difficult.”

He added that Ghana, as the first country to approve the vaccine, represents a “significant milestone in our efforts to combat malaria around the world.”